A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
Determine the 6-month progression free survival (PFS) rate associated with cixutumumab in
combination with depot octreotide acetate (octreotide) in participants with metastatic
neuroendocrine tumors.